Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Asha Pai Scholarship for Excellence in Pharmacy Todays episode is an interview with Nesha Pai, Dr
Q: Who is this product for
DOI: 10.1016/j.peptides.2005.01.029 Clinical Development Afamelanotide and EPP Afamelanotide (MT-1), delivered as a subcutaneous slow-release implant, has been studied in multiple randomised controlled trials in patients with erythropoietic protoporphyria (EPP)
Levels decline with age and drop further in chronic disease, including Parkinson's disease, liver disease, heart disease, and alcohol use disorder
Our study found that over an average follow-up of 2 years, GLP-1 RA use was associated with a significantly lower incidence of cancers directly fueled by excess body weight
These data are available on request to the Peter MacCallum Cancer Centre Data Access Committee ([email protected])
